Gilead asks FDA to expand exclusivity for a key HIV drug

(By Ed Silverman for STAT)

n the latest development in a heated battle between Gilead Sciences and the US Food and Drug Administration, the company petitioned1 the agency this month to retroactively grant five years of exclusive marketing for an HIV medicine. And the drug maker argues that it otherwise faces lost sales and added expense from fending off a pending generic threat to its Stribild medication. Continue reading article here……

stat-logo

 

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.